Paper326003
Passive immunotherapy of cancer in animals and man.
Rosenberg SA and 1 other. Adv Cancer Res, 1977. Cited by 130 papers, by iCite.
11 sourcespapers-2026-11-12-0.1.0
Cite this record
ConductScience Library. Passive immunotherapy of cancer in animals and man. Papers, record 326003. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/326003
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics21
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Immunization, Passive | Major topic |
| Neoplasms | Major topic |
| Animals | |
| Antibodies | |
| Antibodies, Heterophile | |
| Antineoplastic Agents | |
| Binding, Competitive | |
| Bone Marrow | |
| Bone Marrow Cells | |
| Bone Marrow Transplantation | |
| Humans | |
| Immunotherapy | |
| In Vitro Techniques | |
| Isoantibodies | |
| Lymphocyte Transfusion | |
| Lymphocytes | |
| Neoplasms, Experimental | |
| RNA | |
| Subcellular Fractions | |
| Transfer Factor | |
| Transplantation, Homologous |
Source PubMed
Cited by58
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 130 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42,482,408 | Tumor-infiltrating lymphocyte (TIL) therapy: Historical context, clinical applications, and future directions. | Cancer | 2026 | https://conductscience.org/library/papers/42482408 | PubMed |
| 40,900,811 | Cancer Immunotherapy in Combination with Radiotherapy and/or Chemotherapy: Mechanisms and Clinical Therapy. | MedComm (2020) | 2025 | https://conductscience.org/library/papers/40900811 | PubMed |
| 38,085,594 | Polyclonal antibodies selectively inhibit tumor growth and invasion and synergize with immune checkpoint inhibitors. | JCI Insight | 2024 | https://conductscience.org/library/papers/38085594 | PubMed |
| 36,941,828 | A Review of CAR-T Therapy in Pediatric and Young Adult B-Lineage Acute Leukemia: Clinical Perspectives in Singapore. | Onco Targets Ther | 2023 | https://conductscience.org/library/papers/36941828 | PubMed |
| 34,386,077 | Cancer immunotherapy: A comprehensive appraisal of its modes of application. | Oncol Lett | 2021 | https://conductscience.org/library/papers/34386077 | PubMed |
| 33,824,633 | Smarter cures to combat COVID-19 and future pathogens: a review. | Environ Chem Lett | 2021 | https://conductscience.org/library/papers/33824633 | PubMed |
| 32,432,843 | T Cell Receptor Engineered Lymphocytes for Cancer Therapy. | Curr Protoc Immunol | 2020 | https://conductscience.org/library/papers/32432843 | PubMed |
| 32,418,986 | Genetically engineered mesenchymal stem cells: targeted delivery of immunomodulatory agents for tumor eradication. | Cancer Gene Ther | 2020 | https://conductscience.org/library/papers/32418986 | PubMed |
| 30,555,581 | Adoptive Cell Transfer: Is it a Promising Immunotherapy for Colorectal Cancer? | Theranostics | 2018 | https://conductscience.org/library/papers/30555581 | PubMed |
| 30,194,234 | Radioactive (90Y) upconversion nanoparticles conjugated with recombinant targeted toxin for synergistic nanotheranostics of cancer. | Proc Natl Acad Sci U S A | 2018 | https://conductscience.org/library/papers/30194234 | PubMed |
| 29,396,610 | Arsenic trioxide: insights into its evolution to an anticancer agent. | J Biol Inorg Chem | 2018 | https://conductscience.org/library/papers/29396610 | PubMed |
| 28,845,462 | Potential Cancer Prevention and Treatment by Silencing the Killer Cell Immunoglobulin-like Receptor Gene in Natural Killer Cells Derived from Induced Pluripotent Stem Cells. | Enliven J Stem Cell Res Regen Med | 2016 | https://conductscience.org/library/papers/28845462 | PubMed |
| 27,372,731 | Chimeric antigen receptors: driving immunology towards synthetic biology. | Curr Opin Immunol | 2016 | https://conductscience.org/library/papers/27372731 | PubMed |
| 27,081,677 | Antibody Therapeutics in Oncology. | Immunotherapy (Los Angel) | 2016 | https://conductscience.org/library/papers/27081677 | PubMed |
| 24,907,378 | IL-2: the first effective immunotherapy for human cancer. | J Immunol | 2014 | https://conductscience.org/library/papers/24907378 | PubMed |
| 24,274,181 | Chimeric antigen receptor therapy for cancer. | Annu Rev Med | 2014 | https://conductscience.org/library/papers/24274181 | PubMed |
| 22,437,939 | Adoptive immunotherapy for cancer: harnessing the T cell response. | Nat Rev Immunol | 2012 | https://conductscience.org/library/papers/22437939 | PubMed |
| 19,473,517 | Progress and challenges in the vaccine-based treatment of head and neck cancers. | J Exp Clin Cancer Res | 2009 | https://conductscience.org/library/papers/19473517 | PubMed |
| 17,476,350 | Principles of adoptive T cell cancer therapy. | J Clin Invest | 2007 | https://conductscience.org/library/papers/17476350 | PubMed |
| 8,699,241 | Autologous tumor cell vaccination combined with adoptive cellular immunotherapy in patients with grade III/IV astrocytoma. | J Neurooncol | 1996 | https://conductscience.org/library/papers/8699241 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- References
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/326003
GET https://conductscience.org/api/papers/v1/326003/cited_by?page=2